All articles by Staff Writer
Staff Writer
Vazyme Signs Global Strategic Cooperation Agreement with Azenta
Vazyme (688105.SH), China’s leading biotechnology company, has officially signed a global strategic cooperation agreement with Azenta Life Sciences (“Azenta”, Nasdaq: AZTA), which will promote to establish “one-stop” service process for both companies in the fields of next-generation sequencing, automated library preparation, raw material supply, experimental consumables, sample storage and more.
Bruker Introduces Novel EVOQ™ DART-TQ+ for Chromatography-Free Mass Spectrometry Aimed at the Applied Market Segments
At the 71st ASMS meeting, Bruker Corporation (Nasdaq: BRKR) highlights its commitment to develop novel technology and improved mass spec workflows for the applied markets requirements of robustness, ease-of-use, and highest confidence in food/beverage, forensic/toxicology, industrial and environmental analysis.
A.Menarini Diagnostics announces the release of the PRIME MDx platform
A.Menarini Diagnostics S.r.l. is pleased to announce the commercial launch of its PRIME MDx platform: a sample-to-result, all-in-one, fully-automated molecular diagnostics platform for the processing of various testing portfolios through real-time PCR.
Certest Biotec, the University of Zaragoza and the University of the Basque Country are working on developing a new inhaled vaccine against tuberculosis, as a reinforcement of the current and future vaccines
Certest Biotec, a Spanish biotechnology-based company, is leading an ambitious R&D project in collaboration with the University of Zaragoza and the University of the Basque Country (UPV/EHU). The project´s objective is to develop a mRNA vaccine against tuberculosis, as a reinforcement of the current and future vaccines. This project was selected for funding in the framework of collaborative R&D projects for Personalised Medicine and Advanced Therapies within the joint action by the Centre for the Development of Industrial Technology and the Carlos III Health Institute (Spanish Ministry of Science and Innovation).
Africa Health ExCon to Address Expanding Africa’s Vaccine Manufacturing Capacity and Promoting Women’s Health
Hosting More than 1044 Speakers
2nd Edition of Africa Health ExCon to Review Healthcare Quality Improvement in Africa
His Highness Sheikh Hasher bin Maktoum bin Juma Al Maktoum inaugurates 2023 edition of the PrecisionMed Exhibition & Summit
PMES 23 opens in Dubai with leading scientists, physicians, policymakers, entrepreneurs, and investors uniting to drive progress in precision medicine in the region Her Excellency Sarah Al Amiri, Minister of State for Public Education and Advanced Technology, explained that key stakeholders in healthcare must “draw on our combined strength to drive further progress in healthcare” PMES 23 takes place 23-24 May 2023 at the Dubai World Trade Centre
New Expert Guidelines from IWGDF Highlight the Growing International Recognition of Topical Oxygen Therapy for Diabetic Foot Ulcers
Evidence-based recommendations support the effective use of TOT in diabetic foot ulcer management, revolutionizing treatment approaches worldwide
Roche commits to diversity & inclusion in the Middle East with the signing of the Middle East Inclusion & Diversity Council Charter
Roche in the Middle East has reaffirmed its commitment to diversity and inclusion by signing the Middle East Inclusion & Diversity Council Charter. The company is among the latest companies that have pledged to accelerate greater gender balance in the region in line with the UN’s fifth sustainable development goal, which encourages an increase in the ratio of women in leadership positions to 30 percent by 2025.
Leading healthcare experts from MENA and beyond to explore the future of precision medicine in the region at PMES 23 this month
The future of medicine in the Middle East and North Africa is precise By 2030, the global market for precision medicine is expected to exceed $175bn PMES 23 is generously supported by the UAE’s MoIAT, MoHAP, DoH Abu Dhabi, and the DHA PMES 23 takes place 23-24 May 2023 at the Dubai World Trade Centre
Illumina’s genomic technologies enable better pathogen preparedness and response
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today recognized the progress and impact of genomic technologies on pathogen preparedness and response. Following the boost in sequencing infrastructure and capabilities driven by the COVID-19 pandemic, today genomic technologies are enabling public health agencies and health care systems to better prepare for, and respond to, pathogenic threats.